Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma

Phase I testing of the hu14.18-IL2 immunocytokine (IC) in melanoma patients showed immune activation, reversible toxicities, and a maximal tolerated dose of 7.5 mg/m(2)/day. Preclinical data in IC-treated tumor-bearing mice with low tumor burden documented striking antitumor effects. Patients with c...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Immunol Immunother
Glavni autori: Albertini, Mark R., Yang, Richard K., Ranheim, Erik A., Hank, Jacquelyn A., Zuleger, Cindy L., Weber, Sharon, Neuman, Heather, Hartig, Greg, Weigel, Tracey, Mahvi, David, Henry, Mary Beth, Quale, Renae, McFarland, Thomas, Gan, Jacek, Carmichael, Lakeesha, Kim, KyungMann, Loibner, Hans, Gillies, Stephen D., Sondel, Paul M.
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2018
Teme:
Clinical Trial Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6168354/
https://ncbi.nlm.nih.gov/pubmed/30073390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-018-2223-z
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items